Home·Stocks·IMRX

IMRX

Nasdaq

Immuneering Corporation

Basic Materials · Pharmaceutical Preparations

Research view

Fundamentals · SEC EDGAR · FY 2023-12-31

Revenue & Earnings — fiscal year

🔒 price chart needs market-data feed

$2.3M

2020

$2.1M

2021

$316,952

2022

2023

Snapshot

SEC EDGAR · FY 2023-12-31

Revenue$0

Net Income—

Gross Profit—

Oper Income$-59.4M

EPS (dil)$-1.27

Rev/sh$0.00

FCF/sh$-1.75

Book/sh$3.49

Gross M—

Oper M—

Profit M—

FCF M—

ROE—

ROA—

ROIC-190.5%

R&D/Rev—

Rev Y/Y—

Rev 3Y CAGR-100.0%

EPS Y/Y37.7%

EPS 3Y CAGR—

FCF 3Y CAGR—

Payout—

Div/sh—

Shs Chg Y/Y+46.8%

Current Ratio11.35

Quick Ratio—

Debt/Eq—

Int Coverage—

Net Debt—

Total Debt—

Cash & Eq$59.4M

Total Assets$102.6M

Oper CF$-45.3M

Capex$142,226

Free CF$-45.5M

Buybacks—

Equity$90.6M

Liabilities$12.0M

Shs Outstand0.03B

SectorBasic Materials

🔒 P/E—

🔒 Fwd P/E—

🔒 P/S—

🔒 P/B—

🔒 Market Cap—

🔒 Div Yield—

🔒 52W Range—

🔒 Beta—

40+ fundamentals — free from SEC EDGAR (public domain). Only the 🔒 price-derived column needs a market-data feed.

Financials — annual

SEC EDGAR · last 4 FY

USD	FY2020	FY2021	FY2022	FY2023
Revenue	$2.3M	$2.1M	$316,952	$0
Gross Profit	$1.0M	$926,888	$158,830	$0
Operating Income	$-17.1M	$-33.9M	$-51.7M	$-58.4M
Net Income	$-17.0M	$-33.5M	$-50.5M	$-53.5M
Diluted EPS	$-3.44	$-2.46	$-1.91	$-1.88
Operating Cash Flow	$-14.6M	$-30.9M	$-44.1M	$-49.0M
Free Cash Flow	$-14.7M	$-30.9M	$-44.8M	$-49.3M

COMMUNITY · $IMRX0 theses

POST YOUR TAKE →

Ask AI about IMRX Build basket with IMRX Screener

Fundamentals sourced from SEC EDGAR filings (public domain). For informational purposes only. Not investment advice.